Business Wire

Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA ® (finerenone)

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new cardiovascular (CV) and renal subgroup analyses for KERENDIA ® (finerenone) from the comprehensive clinical trial program, including the ...
Monthly Prescribing Reference

Kerendia Label Updated With CV Outcomes Data From the FIGARO-DKD Study

Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...
Business Wire

Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to ...
TCTMD

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

(UPDATED) For patients with type 2 diabetes and mild-to-moderate renal disease, finerenone (Bayer AG) significantly cuts the risk of major cardiovascular events, a benefit largely the result of ...
Pharmabiz

Bayer’s Kerendia gets updated label in US to include findings from phase III FIGARO-DKD cardiovascular outcomes study

Bayer announced that it received approval from the US Food and Drug Administration (FDA) for a label update for Kerendia (finerenone) to include findings from the phase III FIGARO-DKD cardiovascular ...